


CLAIMS:

1. The use of a growth hormone secretagogue and a PDE4 inhibitor for the manufacture of a medicament for treatment or prevention of a disease associated with the deposition of β -amyloid in the brain.
5
2. Use according to claim 1 wherein said disease is Alzheimer's disease.
3. The use of growth hormone secretagogue and a PDE4 inhibitor for the manufacture of a medicament for treatment, prevention or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, multi-infarct dementia, dementia pugilistica or Down syndrome.
10
4. Use according to any previous claim wherein said medicament is for administration to a patient suffering from MC1.
15
5. Use according to claim 4 wherein said patient possesses one or more additional risk factors for developing Alzheimer's disease selected from: a family history of the disease; a genetic predisposition to the disease; elevated serum cholesterol; adult-onset diabetes mellitus; lowered baseline hippocampal volume; elevated CSF levels of total tau; elevated CSF levels of phospho-tau; and lowered CSF levels of A β 42.
20
6. Use according to any of claims 1-5 wherein the growth hormone secretagogue is the methanesulfonate salt of N-[1(R)-[(1,2-dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethoxy)ethyl]-2-amino-2-methylpropanamide.
25
7. Use according to any of claims 1-6 wherein the the PDE4 inhibitor is the benzenesulfonate salt of 6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[3-[(E)-2-[3-methyl-1,2,4-oxadiazol-5-yl]-2-[4-(methylsulfonyl)phenyl]ethenyl]phenyl]quinoline or N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-
30

dihydro[1,8]naphthyridin-4-one-3-carboxamide, or a pharmaceutically acceptable salt thereof.

8. The combination of a growth hormone secretagogue and a PDE4 inhibitor for use in treatment or prevention of a disease associated with deposition of β -amyloid in the brain, in particular Alzheimer's disease.

9. A pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula I or a pharmaceutically acceptable salt thereof,



and the compound N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide, or a pharmaceutically acceptable salt thereof.

10. A kit comprising a first medicament comprising a GHS and a second medicament comprising a PDE4 inhibitor together with instructions for administering said medicaments sequentially or simultaneously to a patient suffering from AD, age-related cognitive decline, MCI, cerebral amyloid angiopathy, multi-infarct dementia, dementia pugilistica or Down syndrome.